For many patients using newer weight-loss medications, losing weight may be only the first part of a larger medical conversation: What happens if treatment stops?
Medications such as semaglutide and tirzepatide have transformed obesity treatment by helping many patients achieve significant weight loss, but researchers continue studying what happens after patients discontinue therapy.
Clinical trials show that many people regain some weight after stopping treatment, raising questions about whether these medications should be viewed as short-term interventions or longer-term treatments for a chronic disease.
The issue is particularly relevant in Texas, where obesity remains a significant public health concern. According to the Texas Department of State Health Services, obesity is associated with increased risks for conditions including heart disease, stroke, and type 2 diabetes.
How GLP-1 Medications Changed Weight-Loss Treatment
GLP-1 medications were originally developed to treat type 2 diabetes but have gained widespread attention for their ability to help regulate blood sugar, reduce appetite, and promote weight loss.
The U.S. Food and Drug Administration has approved several medications in this category, including:
- Semaglutide under the brand name Wegovy for chronic weight management;
- Tirzepatide under the brand name Zepbound for chronic weight management.
According to the FDA’s approval announcement for Wegovy, semaglutide was approved for adults with obesity or overweight with at least one weight-related condition when combined with reduced-calorie diet and increased physical activity.
The FDA approved Zepbound in 2023 for adults with obesity or overweight with at least one weight-related condition.
These medications work by mimicking hormones involved in appetite regulation and blood sugar control, helping patients feel fuller longer and consume fewer calories.
Why Texas Has a Stake in the Obesity Treatment Conversation
Texas has one of the largest populations in the nation, and obesity-related health conditions affect millions of residents.
The Centers for Disease Control and Prevention reports that adult obesity increased risk for:
- Type 2 diabetes;
- Cardiovascular disease;
- High blood pressure;
- Certain cancers;
- Joint problems.
For Texas healthcare systems, employers, and families, the growing use of GLP-1 medications has created new conversations about cost, access, and long-term treatment plans.
What Happens When Patients Stop Taking GLP-1 Drugs?
One of the biggest unanswered questions has been whether patients can maintain weight loss after stopping medication.
A follow-up analysis from the STEP 1 clinical trial examined what happened after participants stopped taking semaglutide. During the original 68-week trial, participants receiving semaglutide lost an average of 17.3% of their body weight. After stopping treatment, participants regained an average of 11.6 percentage points of body weight over the following year. Researchers reported that participants regained approximately two-thirds of their previous weight loss.
The findings did not mean every patient regained all lost weight. Instead, researchers found that many patients experienced some degree of weight regain after medication was discontinued.
Facial Changes and Loose Skin After Significant Weight Loss
Rapid weight loss with GLP-1 medications can sometimes lead to noticeable changes in facial appearance, popularly called “Ozempic face.” This is not a direct side effect of the drug itself but results from the loss of facial fat pads, which can cause a gaunt or aged look (sunken cheeks, more prominent wrinkles, or sagging skin).
Similar skin laxity can occur on the body.
Gradual weight loss, adequate protein intake, strength training, and, in some cases, dermatologic or plastic-surgery interventions (fillers, skin-tightening procedures) may help mitigate these effects. Patients concerned about appearance changes should discuss them with their physician or a specialist.
Are GLP-1 Medications Intended to Be Taken Long Term?
Doctors generally consider obesity a chronic disease rather than a temporary condition.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) notes that successful weight management often requires long-term approaches, including lifestyle changes, behavioral strategies, and, for some patients, medication.
Clinical trials suggest continued treatment can help maintain weight loss.
In the SURMOUNT-1 trial, researchers studied tirzepatide in adults with obesity or overweight without diabetes. After 72 weeks, participants receiving tirzepatide experienced substantial weight reductions compared with placebo. Gastrointestinal side effects were the most commonly reported adverse events, particularly during dose escalation.
A later three-year analysis of SURMOUNT-1 found continued weight reduction and reduced progression to type 2 diabetes among participants receiving tirzepatide.
Why Do Some Patients Stop Taking GLP-1 Medications?
Patients discontinue GLP-1 medications for a variety of reasons.
Common factors include:
Cost and Insurance Coverage
Coverage varies significantly among insurance plans. Some patients face high out-of-pocket costs, especially when medications are prescribed for weight management rather than diabetes.
Side Effects
The most commonly reported side effects include:
- Nausea;
- Vomiting;
- Diarrhea;
- Constipation;
- Abdominal discomfort.
The FDA lists gastrointestinal reactions among the most common side effects associated with semaglutide and tirzepatide products.
Weight-Loss Goals
Some patients stop treatment after reaching a personal weight goal, although research suggests maintaining weight loss may require continued management.
Are There Alternatives to GLP-1 Medications?
GLP-1 medications are not the only medical option for obesity treatment.
Doctors may also recommend:
- Nutrition and lifestyle interventions;
- Behavioral therapy;
- Other FDA-approved weight-management medications;
- Bariatric surgery for eligible patients.
The American Gastroenterological Association recommends using pharmacological treatments for eligible patients with obesity when lifestyle interventions alone are insufficient.
Treatment decisions depend on:
- Body mass index;
- Existing health conditions;
- Medication risks and benefits;
- Patient preferences.
Why Doctors Say These Drugs Are Not “Quick Fixes”
While GLP-1 medications have generated significant attention because of their weight-loss effects, physicians emphasize that obesity is a complex disease influenced by genetics, metabolism, environment, behavior, and other factors.
Drugs can help regulate biological processes involved in appetite and weight control, but maintaining health improvements typically involves continued lifestyle changes.
The Future of Weight-Loss Medicine
Researchers continue studying how GLP-1 medications may be used, whether new drugs can provide greater benefits, and how physicians can determine which patients benefit most from long-term treatment.
The question is shifting from simply “How much weight can someone lose?” to “How can that health improvement be maintained?”
Provided by Dallas Express
